As global markets navigate a landscape of economic uncertainty and mixed signals, with tech stocks in the U.S. recently lagging behind broader indices, investors are increasingly turning their attention to Asia’s high-growth tech sector for potential opportunities. In this environment, identifying strong stocks often involves looking at companies that demonstrate resilience and adaptability amid changing economic forecasts and geopolitical risks, as these qualities can be crucial for sustaining growth in dynamic markets like Asia.
Let’s review some notable picks from our screened stocks.
Simply Wall St Growth Rating: ★★★★★☆
Overview: XD Inc. is an investment holding company that focuses on developing, publishing, operating, and distributing mobile and web games in Mainland China and internationally with a market cap of approximately HK$18.24 billion.
Operations: The company generates revenue primarily through its Game segment, which brought in CN¥2.43 billion, and the TapTap Platform, contributing CN¥1.43 billion. The focus on both game development and the TapTap distribution platform highlights a dual revenue stream strategy within the gaming industry.
XD Inc. has demonstrated a robust trajectory with its revenue expected to surge by 46% to 49% year-over-year, reaching up to RMB 5.04 billion in FY 2024. This growth is complemented by an impressive turnaround from a net loss in FY 2023 to a projected net profit of up to RMB 940 million. The company’s commitment to innovation is evident from its substantial investment in R&D, fostering advancements that keep it competitive within Asia’s tech landscape. Moreover, XD’s earnings are poised for a significant annual increase of approximately 54.6%, outpacing the regional market growth and indicating potential for sustained upward momentum in its financial performance.
SEHK:2400 Revenue and Expenses Breakdown as at Mar 2025
Simply Wall St Growth Rating: ★★★★★★
Overview: Ascentage Pharma Group International is a clinical-stage biotechnology company focused on developing therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China, with a market cap of approximately HK$12.61 billion.
Operations: The company generates revenue primarily through the development and sale of novel small-scale therapies, amounting to CN¥903.03 million.
Ascentage Pharma Group International has shown a notable rebound in its financial performance, with sales soaring to CNY 980.65 million in FY 2024 from CNY 221.98 million the previous year, reflecting a remarkable growth trajectory despite the company’s net loss narrowing significantly to CNY 405.43 million from CNY 925.64 million. This improvement is underpinned by strategic R&D investments that fuel innovation across its robust pipeline, highlighted by recent breakthroughs like olverembatinib receiving multiple Breakthrough Therapy Designations in China for critical leukemia treatments. These advancements not only underscore Ascentage’s commitment to addressing unmet medical needs but also position it well within the high-stakes biotech sector where it continues to push scientific boundaries at major forums like the AACR Annual Meeting.
SEHK:6855 Earnings and Revenue Growth as at Mar 2025
Simply Wall St Growth Rating: ★★★★★☆
Overview: Genew Technologies Co., Ltd. is involved in the global research, development, production, and sale of communication and network products with a market capitalization of CN¥5.73 billion.
Operations: Genew Technologies Co., Ltd. focuses on the global research, development, production, and sale of communication and network products. The company operates with a market capitalization of CN¥5.73 billion.
Genew Technologies Co., Ltd. has pivoted impressively from a net loss to profitability, showcasing a robust annual revenue growth of 30.6% and an even more striking earnings growth of 71%. This performance outpaces the broader Chinese market’s average, indicating strong operational efficiency and market acceptance. The shift to profitability is underscored by a recent earnings report for FY 2024, where sales climbed to CNY 950.22 million from CNY 884.41 million the previous year, and net income reached CNY 27.11 million, reversing the prior year’s loss of CNY 86.56 million. This financial turnaround is particularly noteworthy in the context of its R&D commitment—integral to its strategic positioning within Asia’s competitive tech landscape—highlighting Genew’s potential trajectory in influencing regional tech innovation trends.
SHSE:688418 Revenue and Expenses Breakdown as at Mar 2025
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include SEHK:2400 SEHK:6855 and SHSE:688418.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
Download 
Download 
